Granuloma faciale (GF) is a chronic cutaneous condition that can persist despite pharmacological management. When disease proves resistant to drug-based therapy, physical and surgical modalities become the next therapeutic consideration, with the clinical objective of achieving clearance of granuloma faciale lesions.

Clinical Situation

This protocol is intended for patients with granuloma faciale in whom the condition has not responded adequately to prior medical treatment — drug-resistant disease — and who require a physical or procedural intervention to achieve lesion clearance.

Treatment Approach (Partial Overview)

Management in this setting centres on physical and surgical modalities. A laser-based intervention forms a key part of the approach, with modality selection guided by local availability and clinical factors.

The complete structured regimen — including specific modality selection, sequencing, and all relevant clinical considerations — is available via the protocol link below.

Treatment Goal

The primary clinical objective is clearance of granuloma faciale lesions.

References

DOI: 10.2340/00015555-2784

Based on our own experience, we suggest the use of laser, preferably PDL laser if available, as the treatment of choice for drug-resistant GF.
Ludwig et al. (16) used a KTP 532-nm laser because of its known success in the treatment of vascular lesions.
Bakkour & Madan (50) successfully treated a rhinophyma-like GF with a CO2 laser.
Cryotherapy is inexpensive and widely accessible, but its effect is limited.
By changing pulse durations and energies, most patients' lesions cleared in 2–3 treatments.

View source ↗

Treatment of Drug-Resistant Granuloma Faciale

References